American College of Rheumatology

Pharmacokinetics and immunogenicity were also similar between reference tocilizumab and CT-P47.

At 16 weeks, patients treated with bimekizumab reported greater improvements in both mean spine pain and morning stiffness when compared with placebo. These improvements continued through week 52.

Sustained remission was observed in more patients receiving rituximab and concomitant avacopan compared with those treated with concomitant prednisone.

The most successful outcomes were observed in patients with at least 6 months of pegloticase therapy who promptly began oral therapy within 60 days.

The study revealed that patients meeting fibromyalgia criteria or displaying fibromyalgia-like symptoms were less likely to meet standardized response criteria with biologic therapy.

Diana Abdueva, PhD, states selecting the right therapy for rheumatoid arthritis is a complex challenge due to both the economic burden of therapies and the trial-and-error process patients often undergo.

The 148-week study evaluated multiple domains of patients with psoriatic arthritis receiving risankizumab treatment, providing insights into patients' improvement over time.

Ryan DeMasi, MD, explained despite the patients' shorter disease duration, they exhibited severe symptoms, prompting a more aggressive early intervention approach using treatment with upadacitinib.

Ryan DeMasi, MD, explained the direct and indirect effects of upadacitinib and adalimumab on pain in patients with rheumatoid arthritis.

Patients with PsA in the self-reported racial and ethnic minority were less likely to be diagnosed within 12 months of symptom onset and were more frequently uninsured compared with White patients .

Jawaheer and her team used pre-pregnancy data to determine whether there are gene expression biomarkers at the pre-pregnancy baseline that can predict improvement or worsening during pregnancy in patients with rheumatoid arthritis.

Investigators believe targeted immunomodulation with SEL-212 may have the potential to introduce a new uricase-based therapy for patients with gout refractory to conventional treatment.

The study shows rosnilimab's specificity in targeting PD-1 positive T cells, especially the PD-1 high T cells prevalent in inflamed tissues.

Patients with systemic lupus erythematosus exhibited comparable or higher incidence rates of infection in the placebo cohort compared with belimumab.

A secukinumab researcher explains why the practice may become the "next stethoscope" of medicine.

New findings show a unique series of markers could indicate particular black SLE patient risks.

A real-world study shows the therapy was slightly more efficacious for biologic-naive PsA patients.

A systematic review suggests patients taking immunosuppressive therapy may not be at as heightened risk of infection as previously thought.

An interview with a study author on the promising findings, and the use of ultrasonography in assessing psoriatic arthritis treatment.

Children hospitalized from the condition face a 14-fold increased risk of MACE.

The world is suddenly fixed on the field's most promising agents for an unprecedented virus. It's created a unique situation for specialists to collaborate.

The common rheumatic drug was found in a cohort analysis to be linked to greater regional TB outbreaks.

Less than 2% of surveyed families with rheumatic-disease children had reported a COVID-19 case in the early pandemic—and even fewer had physician-confirmed symptoms.

A discussion on how the pandemic has burdened and, in some ways, bettered the very involved specialty.

Patients with persistently active systemic lupus erythematosus (SLE) benefit from repository corticotropin injection (RCI).